Influence of Recombinant Human Erythropoietin Therapy on Plasma Endothelin-1 Levels during Hemodialysis
| Autor: | Heintz B, Mertens Pr, I. Stefanidis, P. Wurth, Makropoulos W, R. Bach, H. Mann |
|---|---|
| Rok vydání: | 2001 |
| Předmět: |
medicine.medical_specialty
business.industry Anemia medicine.medical_treatment 030232 urology & nephrology Biomedical Engineering Urology Medicine (miscellaneous) Bioengineering Blood volume General Medicine 030204 cardiovascular system & hematology medicine.disease Hemoconcentration Endothelin 1 End stage renal disease Biomaterials 03 medical and health sciences 0302 clinical medicine Blood pressure Erythropoietin medicine Hemodialysis business medicine.drug |
| Zdroj: | The International Journal of Artificial Organs. 24:367-373 |
| ISSN: | 1724-6040 0391-3988 |
| DOI: | 10.1177/039139880102400608 |
| Popis: | The correction of anemia with human recombinant erythropoietin (rHuEPO) in end stage renal disease is associated with hypertension in about one third of hemodialysis patients. The pathogenesis of the rHuEPO-induced hypertension is still uncertain, though evidence of the involvement of endothelial cells has emerged. The aim of this study was to determine plasma endothelin-1 during hemodialysis and to compare the endothelin-1 levels in hemodialysis patients with and without rHuEPO substitution. Nineteen stable patients (13 male and 6 female, mean age 62 ± 11 years) with end stage renal disease were studied. Cuprophan dialysers (GFS 12®, Gambro, Lund, Sweden) were used for hemodialysis in all cases. rHuEPO (40U/kg s.c.) was administered to 10 patients. Blood pressure (BP; RR mmHg) and blood volume changes (ΔBV; hemoglobinometry %) were serially measured. Samples were taken before and every hour during hemodialysis. Plasma endothelin-1 was measured by ELISA (R&D Systems, Minneapolis, USA) and corrected for hemoconcentration. Endothelin-1 concentration was elevated before commencement of hemodialysis (1.16 ± 0.36 pg/ml) when compared to healthy controls (ref. 0.3 - 0.9) and increased to 1.47 ± 0.51 pg/ml by the end of the session (p Plasma endothelin-1 was higher in hemodialysis patients and there was a continuous rise in plasma endothelin-1 during a session. Comparison of two groups of hemodialysis patients with and without s.c. rHuEPO-replacement treatment revealed a significantly higher plasma endothelin-1 concentration in patients with s.c. rHuEPO treatment. However, the elevated endothelin-1 levels were not accompanied by arterial hypertension. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|